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Fibroblast growth factor receptor-1c (FGFR1c)/bKlotho (KLB) complex is a receptor of ﬁbroblast growth
factor 21 (FGF21). Pharmacologically, FGF21 shows anti-obesity and anti-diabetic effects upon peripheral
administration. Here, we report the development of an artiﬁcial peptide agonist to the FGFR1c/KLB
heterodimer complex. The peptide, F91-8A07 (LPGRTCREYPDLWWVRCY), was discovered from random
peptide T7 phage display and selectively bound to the FGFR1c/KLB complex, but not to FGFR1c and KLB
individually. After subsequent peptide dimerization using a short polyethyleneglycol (PEG) linker, the
dimeric F91-8A07 peptide showed higher potent agonist activity than that of FGF21 in cultured primary
human adipocytes. Moreover, the dimeric peptide led to an expression of the early growth response
protein-1 (Egr-1) mRNA in vivo, which is a target gene of FGFR1c. To the best of our knowledge, this is the
ﬁrst report of a FGFR1c/KLB complex-selective artiﬁcial peptide agonist.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Receptor tyrosine kinase (RTK) is one of the common drug tar-
gets. In the past decade, peptides mimicking the function of a
natural RTK ligand have been studied. The most successful example
is erythropoietin (EPO) mimicking peptide: hematide [1e4]. It was
discovered from random peptide phage display and has no
sequence similarity with EPO. Peptide display technologies, such as
phage display, ribosome display, and mRNA display, have been
powerful tools in identifying novel target-binding peptides [5e7].
In recent years, Suga lab of Tokyo University reported an artiﬁcial
Met agonist that was discovered from mRNA display [8]. On the
other hand, there are few reported artiﬁcial agonists to RTKs,
indicating the difﬁculty in generation of such peptides.
FGFR1c is one of RTKs and a receptor of FGF21. The pharmaco-
logical actions of FGF21 are as follows: anti-obesity effects, ach-
ieved by increasing energy expenditure to reduce body weight;eptor; KLB, bKlotho; FGF21,
Egr-1, early growth response
K. Sakamoto).
Inc. This is an open access article uanti-diabetic effects, achieved by decreasing blood glucose, insu-
lin, triglycerides, LDL, and cholesterol levels; and improving insulin
sensitivity and hepatic steatosis [9e11]. FGFR1c is activated by ca-
nonical FGFs through receptor-homodimerization. However, unlike
canonical FGFs, FGF21 is not able to interact directly with FGFR1c. It
depends on KLB as a co-receptor for interactionwith FGFRs for their
activation [12e14]. Recent studies suggested that the C-terminus of
FGF21 binds directly to KLB, and the N-terminus is important to
activate FGFR1c, but the detailed mechanism of receptor activation
by FGF21 is not fully understood [15e17].
In this study, we hypothesized that acceleration/stabilization
ability of FGFR1c/KLB complex formation and dimerization ability
of FGFR1c would be required for molecules that have FGF21-like
agonist activity. To test these two features, we searched for
FGFR1c/KLB complex-selective peptide from random peptide T7
phage display. We isolated one phage clone that selectively binds to
FGFR1c/KLB complex, but not to FGFR1c and KLB individually. After
subsequent peptide dimerization by a chemical linker, we suc-
cessfully generated an artiﬁcial peptide agonist to FGFR1c/KLB.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Binding activity of F91-8A07 phage and its synthetic peptide. (A) Binding ac-
tivity of F91-8A07 phage to puriﬁed recombinant proteins. The binding was detected
by anti-T7 phage antibody-HRP and was measured by absorbance at 450 nm. (B)
Binding-activity and -selectivity of biotinylated F91-8A07 peptide to puriﬁed recom-
binant proteins. Binding activity was detected by SA-HRP and was measured by
chemical luminescence. (C) Ligand competitiveness of F91-8A07 peptide. Vertical line
is shown as a relative % value against the binding of biotinylated peptide (1 nM) to
human HD in the absence of FGF ligands.
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2.1. Preparation of FGFR1c/KLB-Fc heterodimer
The plasmids for protein preparation were kindly gifted from
National Institute of Advanced Industrial Science and Technology
(AIST, Tsukuba, Japan). A stable mammalian cell line expressing
human KLB(1-994)-V5-His-Fc was established from FreeStyle293
(Thermo Fisher Scientiﬁc, MA, USA) cells transfected with
pcDNA3.1/human KLB(1-994)-V5-His-Fc, using G418 as a selection
marker. To express human KLB(1-994)-V5-His-Fc and human
FGFR1Cv2(1-376)-Fc heterodimer, pcDNA3.1/human FGFR1Cv2(1-
376)-Fc were transfected into the cells expressing human KLB(1-
994)-V5-His-Fc. Human KLB(1-994)-V5-His-Fc/human
FGFR1Cv2(1-376)-Fc heterodimer was puriﬁed from the culture
supernatant by NiNTA Superﬂow cartridge (QIAGEN, Hilden, Ger-
many) afﬁnity chromatography and HiLoad 26/60 Superdex 200 pg
(GE Healthcare, Chalfont St. Giles, UK) gel ﬁltration
chromatography.
2.2. Phage library construction and panning
The T7 phage libraries displaying random peptides were con-
structed using mixed-oligonucleotides as template DNA and T7
Select 10-3 vector from Merck Millipore (Darmstadt, Germany),
according to the methods described previously [5e7]. Recombinant
Fc-fused protein was immobilized to Dynabeads Protein A/G
(Invitrogen, CA, USA) with 0.5% BSA in PBS. After washing the beads
by PBS containing 0.1% Tween20 (PBST), the beads were incubated
with phage library for 1 h and were washed with PBST. The bound
phages were eluted by 1% SDS and were introduced in Escherichia
coli BLT5615 cells (Merck Millipore, Darmstadt, Germany) in log-
phase growth for phage ampliﬁcation. After bacteriolysis, the
phages were recovered from the culture supernatant by centrifu-
gation and PEG-precipitation. The recovered phages were sus-
pended in PBS and used for the next round of panning.
2.3. Dimerization of F91-8A07 peptide with a chemical linker
Peptide and triethylamine (12 equivalents) was dissolved in
DMF. To the solution of peptide 0.1 M 4-dimethylaminopyridine in
DMF (0.1 equivalents) and a chemical linker, Fmoc-N-(PEG3-OSu)2
(bis(2,5-dioxopyrrolidin-1-yl) 10-(((9H-ﬂuoren-9-yl)methoxy)
carbonyl)-4,7,13,16-tetraoxa-10-azanonadecane-1,19-dioate)
(M03436, Watanabe Chemical Instituted, Hiroshima, Japan) or
Fmoc-N-(PEG6-OSu)2 (bis(2,5-dioxopyrrolidin-1-yl) 19-(((9H-ﬂuo-
ren-9-yl)methoxy)carbonyl)-4,7,10,13,16,22,25,28,31,34-decaoxa-
19-azaheptatriacontane-1,37-dioate) (M03479, Watanabe Chemi-
cal Instituted, Hiroshima, Japan), in DMF (0.5 equivalents) was
added. The reaction mixture was mixed for 2 h, followed by addi-
tion of diethylamine to remove Fmoc. Aftermixing for 15min, 0.1M
acetic acid was added to stop the reaction. The mixture was ﬁltered
through PTFE membrane ﬁlters, and puriﬁed by RP-HPLC (phe-
nomenex C18, 4.64  150 mm). Pure fractions were collected and
lyophilized to yield dimeric peptide as a white powder.
2.4. Evaluation of phage- or synthetic peptide-binding to
recombinant proteins by ELISA
Human FGFR3-Fc was purchased from R&D Systems (MN, USA).
Mouse FGFR1c-Fc, mouse KLB-Fc, human KLB-Fc were prepared
internally by using a proprietary vector and expression in Free-
Style293 (Thermo Fisher Scientiﬁc, MA, USA) cells. The wells of a
Nunc Maxisorp microplate (460-518) were coated with an anti-
human Fc goat polyclonal antibody (Jackson ImmunoResearch,PA, USA) and blocked with 0.5% BSA in PBS. Fc-fused proteins were
captured by the antibody, and phage solution or biotinylated pep-
tide solution was added to the wells. After washing with PBST,
bound phages or peptides were detected using horseradish
peroxidase (HRP)-conjugated anti-T7 antibody (Merck Millipore,
Darmstadt, Germany) or HRP-conjugated streptavidin (VECTOR
Laboratories Inc., CA, USA), respectively. The amounts of HRP in
wells were measured by detection reagents tetramethylbenzidine
(Wako, Osaka, Japan) or a chemical luminescent reagent (Wako,
Osaka, Japan).
2.5. Evaluation of agonistic activity of the synthetic peptide in cells
Human primary visceral pre-adipocytes (lot. 8F3482) were
purchased from Lonza (Basel, Switzerland) and their differentiation
to adipocytes was achieved according to the manufacturer's pro-
tocols. The differentiated human primary adipocytes were plated
on a poly-D-Lys coated plate and incubated with PGM2 medium
(Lonza), respectively. After exchanging the medium with PBM2
containing 0.1% BSA, the cells were starved for 24 h. The peptides
diluted with PBS containing 0.1% BSA were added to the wells, and
the cells were incubated for 10 min at 37 C. After removing the
K. Sakamoto et al. / Biochemical and Biophysical Research Communications 480 (2016) 55e60 57peptide solution, the wells were washed once with PBS and added
to cell lysis buffer. The phosphorylated Erk1/2 in cell lysate was
measured by Alphascreen (Perkinelmer, MA, USA), according to the
manufacturer's protocols.
2.6. Animals
Male C57BL/6J mice were purchased from CLEA Japan, Inc.
(Tokyo, Japan). Mice were maintained under controlled tempera-
ture (20e26 C), humidity (40e70%), and a 12 h light-dark cycle
(lights on 7 a.m.) with free access to food (CE-2, CLEA Japan, Inc.)
and water. All animal experiments were conducted in accordance
with the protocols reviewed by the Institutional Animal Care and
Use Committee of Takeda Pharmaceutical Co., Ltd.
2.7. Evaluation of agonist activity of synthetic peptide in vivo
N-(PEG3-LPLP-8A07)2 and FGF21 were dissolved in 10% DMSO/
saline. The mice were administered vehicle, N-(PEG3-LPLP-8A07)2
(10 nmol/kg, 100 nmol/kg, 1000 nmol/kg) or FGF21 (10 nmol/kg)
subcutaneously (n ¼ 5), and the tissues were excised under anes-
thesia 1 h after injection. Total RNA was isolated from the liver and
brown adipose tissue (BAT) using QIAzol reagent (QIAGEN, Hilden,
Germany) and cDNA was synthesized using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA). Quantitative RT-PCR was performed using the ABI Prism
7900 Sequence Detection System with TaqMan Universal PCR
Master Mix (Applied Biosystems). Mixtures of primers and probes
(Applied Biosystems) were used for the detection of mRNA
encoding early growth response 1 (Egr-1) protein. The primer and
probe sets of cyclophilin D were synthesized, and the primers wereFig. 2. Binding effect of F91-8A07 peptide on the FGFR1c/KLB complex formation. (A) Effect
mouse KLB-His to mouse FGFR1c-Fc was evaluated in the absence or presence of human FGF
of F91-8A07/FGFR1c/KLB ternary complex.ggtcctggcatcttgtccat (forward), cagtcttggcagtgcagataaaa (reverse),
and ctggaccaaacacaaacggttccca (probe) (Applied Biosystems). The
Egr-1 expression levels were normalized to those of cyclophilin D.
Data are expressed as mean ± standard deviation (SD). Statistical
signiﬁcance between vehicle and FGF21 was analyzed using the
Student t-test or Aspin-Welch test, and dose-dependency of N-
(PEG3-LPLP-8A07)2 was analyzed using the one-tailed Williams
test.3. Results
3.1. Isolation of FGFR1c/KLB-selective binding phage
The mechanism of FGF21-receptor activation is not entirely
clear, but previous studies suggested that acceleration of FGFR1c/
KLB complex formation and subsequent dimerization of FGFR1c are
important [18]. We hypothesized that the molecules binding to
interface of FGFR1c/KLB complex would have a potential agonist
activity. However, as shown in a previous report, the interaction
between FGFR1c and KLB is signiﬁcantly weak in vitro [16], sug-
gesting that such an interface would be unstable for phage panning.
Therefore, we constructed a pseudo-complex: FGFR1c-Fc/KLB-Fc
heterodimer (HD) by fusion of extracellular domains of FGFR1c and
KLB to the Fc region of Immunoglobulin-G. The HD bound to FGF2,
as well as KLB-Fc (data not shown). After 5 rounds of panning
random peptide displayed T7 phage libraries against HD, a total of
752 clones were screened for binding activities to FGFR1c-Fc, KLB-
Fc, and HD. Most clones bound equally to KLB-Fc and HD, indicating
that these clones mainly recognized the KLB region. Others, with
the exception of one, showed equal binding to FGFR1c-Fc and HD,
indicating that these clones mainly recognized the FGFR1c region.of F91-8A07 peptide on the interaction between FGFR1c-Fc and KLB-His. The binding of
21 or F91-8A07 peptide and detected by anti-His antibody-HRP. (B) Interaction scheme
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HD equally, but not to FGFR1c-Fc and KLB-Fc individually (Fig. 1A).3.2. Binding-activity and -selectivity of synthetic F91-8A07 peptide
We chemically synthesized F91-8A07 sequence
(LPGRTCREYPDLWWVRCY) and evaluated its binding activity by
ELISA. Biotinylated F91-8A07 peptide demonstrated a phage form
and selective binding to HDs, but not to FGFR1c, FGFR3, and KLB
individually. The EC50 binding values against human HD andmouse
HD are 0.9 nM and 1.4 nM, respectively (Fig. 1B). Interestingly, theFig. 3. Agonist activity of dimeric F91-8A07 peptide in primary human adipocytes. (A) Agon
adipocytes. Vertical line is shown as counts of total phosphorylated Erk1/2 protein. (B) Inte
design scheme of dimeric F91-8A07 peptide.binding of F91-8A07 peptide to human HDwas not inhibited by the
presence of human FGF1, FGF2, or FGF21 (Fig. 1C).
Would the F91-8A07 peptide accelerate and stabilize the for-
mation of FGFR1c/KLB complex? To answer this question, we used
ELISA to assess the binding between mouse FGFR1c-Fc and mouse
KLB-His in the presence or absence of the F91-8A07 peptide. As
expected, the binding efﬁcacy and potency of KLB-His to FGFR1c-Fc
was dramatically increased in presence of the F91-8A07 peptide
(Fig. 2A). This result demonstrates that the F91-8A07 peptide can
accelerate the formation of FGFR1c/KLB complex (Fig. 2B), and this
ability contributes to its agonistic activity.ist activity of dimeric peptides in cultured primary human visceral pre-adipocytes and
raction scheme of dimeric F91-8A07 peptide with the FGFR1c/KLB complex. (C) Linker
K. Sakamoto et al. / Biochemical and Biophysical Research Communications 480 (2016) 55e60 593.3. Agonist activity of dimeric F91-8A07 peptide to primary human
adipocytes
We evaluated the agonist activity of the monomeric F91-8A07
peptide by measuring phosphorylation of Erk1/2 that is a down-
stream signal of FGFR1c in primary human visceral adipocytes.
Unfortunately, F91-8A07 monomer peptide did not show an
agonistic activity (data not shown). Since receptor homodimeriza-
tion is essential for FGFRs activation, we conjugated N-terminus of
the peptide to three chemical linkers of varying lengths (gGlu,
PEG3, and PEG6), and constructed dimeric F91-8A07 peptides that
would induce tetramerization of the FGFR1c/KLB complex. As ex-
pected, the dimeric peptides showed an agonistic activity according
to the linker length (data not shown). Of them, PEG6-linked dimeric
F91-8A07 peptide showed maximum agonist activity only in adi-
pocytes, but not in pre-adipocytes that do not express KLB (Fig. 3A).
In addition, its agonist potency is higher than that of FGF21. This
result indicates that peptide dimerization by linkage successfully
led to cooperative binding of two F91-8A07 peptides, and induced
receptor tetramerization by forming 2:2:2 complex of F91-8A07/
FGFR1c/KLB (Fig. 3B).
However, the agonist activity showed a bell-shaped distribution
and the intensity was 50%, as comparedwith that of FGF21 (Fig. 3A).
One possible explanation could be binding competitiveness of each
dimeric peptide (Fig. 3B), and we predicted that substitution of the
long ﬂexible PEG6 linker with amino acids would increase the af-
ﬁnity to FGFR1c/KLB and improve the bell-shaped distribution and
partial agonist activity. Accordingly, PEG6 linker was substituted
with a PEG3/tetra-peptide hybrid linker (Fig. 3C), and its agonist
activity was evaluated. We observed that the resulting N-(PEG3-
LPLP-8A07)2 showed relative improvement of bell-shaped
agnostic activity (Fig. 3A).
3.4. Agonist activity of dimeric F91-8A07 peptide in vivo
To investigate whether the dimeric peptide behaves as FGFR1c/
KLB agonist in vivo, we injected (PEG3-LPLP-8A07)2 to C57BL/6J
mice and evaluated the Egr-1 mRNA expression, which is a down-
stream marker of FGFR1c.We found that N-(PEG3-LPLP-8A07)2
signiﬁcantly increased the Egr-1 mRNA expression at doses of
10 nmol/kg, 100 nmol/kg, and 1000 nmol/kg in brown fat adipose
tissue (BAT), suggesting that our dimeric peptide can activate
FGFR1c/KLB in vitro and in vivo (Fig. 4).
4. Discussion
Protein function mimicking peptide, such as an artiﬁcial agonist,
is useful for not only drug itself, but also as a molecular biology tool.Fig. 4. Agonist activity of dimeric F91-8A07 peptide in vivo. Agonist activity of dimeric pepti
FGF21, was measured. Data are means þ SD (n ¼ 5, #P < 0.025 by Williams test, **P < 0.01In this report, we successfully generated an artiﬁcial peptide
agonist to the FGFR1c/KLB complex. The artiﬁcial agonists to
FGFR1c have been also reported from other companies. For
example, Genentech Inc. reported an FGFR1c/KLB bispeciﬁc anti-
body agonist, and Amgen Inc. reported an FGFR1c/KLB bispeciﬁc
protein, as FGF21-mimicking molecules [19,20]. The point that
distinguishes our peptide from the existing ones is the receptor-
binding selectivity. F91-8A07 peptide binds to FGFR1c/KLB com-
plex, but not to FGFR1c and KLB individually, suggesting that our
peptide recognizes the interface of FGFR1c and KLB. This binding
speciﬁcity would avoid side-effects when the F91-8A07 peptide is
used as a lead molecule for a drug. The binding to FGFR1c that is
expressed homeostatically in whole body may induce undesirable
side-effects. Also, while the binding to KLB is needed for tissue-
selective action, it may lead to a loss of circulating efﬁcacy
in vivo, as the molecules will be attached to the KLB expressed in
liver. Therefore, the F91-8A07 peptide would access the FGFR1c/
KLB complex more effectively, as compared to other FGF21
mimetics.
Where is the binding site of F91-8A07? Interestingly, our pep-
tide did not compete for the binding sites with canonical FGFs and
FGF21. As reported, the binding afﬁnity between recombinant KLB
and FGFR is in the order of micro molar [16], suggesting that the
FGFR1c/KLB complex interface is unstable in its natural state.
Therefore, FGF21 could not use the interface and required KLB-
binding for its tissue-selective activity in the process of evolution.
The discovery of F91-8A07 peptide became possible because we
used a pseudo-complex of FGFR1c/KLB with a stable interface. Such
an approach will be effective to generate other protein complex-
selective peptides.
Dimeric F91-8A07 peptide exhibited agonist activity in primary
human adipocytes. Moreover, its potency is higher than that of
FGF21. On the other hand, the agonist, as well as the bispeciﬁc
antibody from Genentech, showed partial activity with a bell-
shaped distribution [19]. As we used a ﬂexible PEG linker,
competitive binding may occur. Though we could not signiﬁcantly
improve the bell-shaped and partial agonist activity in this report,
we consider that further optimization of linker structure and length
will be effective. Interestingly, our dimeric peptide signiﬁcantly
induced Egr-1 mRNA expression only in the adipose tissue, but not
in the liver, whereas KLB is expressed in the liver and the adipose
tissue. Genentech's bispeciﬁc antibody also showed agonist effect
only in adipose tissues and pancreas, which express high levels of
both FGFR1c and KLB, but not in the liver where FGFR1c expression
is much lower than that in adipose tissues [19,21]. In contrast,
FGF21 induces phosphorylation of Erk even in liver through not
only FGFR1c/KLB, but also FGFR3/KLB [22]. These reports support
that F91-8A07 peptide accessed the FGFR1c/KLB complex directlydes in C57BL/6J mice. The expression of Egr-1 mRNA, which is a downstream marker of
by Student's t-test, and xP < 0.05 by Aspin-Welch test).
K. Sakamoto et al. / Biochemical and Biophysical Research Communications 480 (2016) 55e6060and activated it in vivo.
Most importantly, we can generate one of the protein functions
using a mimicking peptide that can activate FGFR1c/KLB complex
by combination of phage display technology and chemical modiﬁ-
cation. F91-8A07 peptide will contribute to study, drug design, and
drug development related to FGFR1c, KLB, and FGF21.
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